{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:51:57Z","timestamp":1790380317786,"version":"4.1.0"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00116","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T09:56:28Z","timestamp":1584093388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Role of the Gut in Diabetic Dyslipidemia"],"prefix":"10.3389","volume":"11","author":[{"given":"Priska","family":"Stahel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changting","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Nahmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the genomic era: a new paradigm","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocr Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00041433-200210000-00001","article-title":"Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis","volume":"13","author":"Proctor","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.bbalip.2011.11.010","article-title":"Pathophysiology of hypertriglyceridemia","volume":"1821","author":"Hassing","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1046\/j.1365-2796.1999.00548.x","article-title":"Postprandial lipoprotein metabolism and atherosclerosis","volume":"246","author":"Karpe","year":"1999","journal-title":"J Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1172\/JCI107334","article-title":"Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man","volume":"52","author":"Brunzell","year":"1973","journal-title":"J Clin Invest."},{"key":"B6","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0022-2275(20)34932-4","article-title":"Hepatic uptake of chylomicron remnants","volume":"38","author":"Cooper","year":"1997","journal-title":"J Lipid Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4239\/wjd.v5.i2.165","article-title":"Origin and therapy for hypertriglyceridaemia in type 2 diabetes","volume":"5","author":"Pang","year":"2014","journal-title":"World J Diabetes."},{"key":"B8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.atherosclerosis.2008.07.046","article-title":"Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance","volume":"204","author":"Laatsch","year":"2009","journal-title":"Atherosclerosis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-nutr-071714-034338","article-title":"New insights into the regulation of chylomicron production","volume":"35","author":"Dash","year":"2015","journal-title":"Annu Rev Nutr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(99)00397-4","article-title":"A proposed model for the assembly of chylomicrons","volume":"148","author":"Hussain","year":"2000","journal-title":"Atherosclerosis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1074\/jbc.M115.683359","article-title":"Characterization of a novel intestinal glycerol-3-phosphate acyltransferase pathway and its role in lipid homeostasis","volume":"291","author":"Khatun","year":"2016","journal-title":"J Biol Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"G628","DOI":"10.1152\/ajpgi.00225.2011","article-title":"Apolipoprotein A-IV regulates chylomicron metabolism\u2013mechanism and function","volume":"302","author":"Kohan","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"G715","DOI":"10.1152\/ajpgi.1986.250.6.G715","article-title":"Formation and transport of chylomicrons by enterocytes to the lymphatics","volume":"250","author":"Tso","year":"1986","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fphys.2020.00004","article-title":"The role of interstitial matrix and the lymphatic system in gastrointestinal lipid and lipoprotein metabolism","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Physiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jcmgh.2018.10.015","article-title":"Regulation of chylomicron secretion: focus on post-assembly mechanisms","volume":"7","author":"Xiao","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"E429","DOI":"10.1152\/ajpendo.00178.2011","article-title":"Gut-liver interaction in triglyceride-rich lipoprotein metabolism","volume":"301","author":"Xiao","year":"2011","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/gut.52.6.834","article-title":"Mobilisation of enterocyte fat stores by oral glucose in humans","volume":"52","author":"Robertson","year":"2003","journal-title":"Gut"},{"key":"B18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jcmgh.2018.10.002","article-title":"Oral glucose mobilizes triglyceride stores from the human intestine","volume":"7","author":"Xiao","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1053\/j.gastro.2010.05.002","article-title":"Dynamics of fat absorption and effect of sham feeding on postprandial lipemia","volume":"139","author":"Chavez\u2013Jauregui","year":"2010","journal-title":"Gastroenterology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MOL.0000000000000495","article-title":"Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2","volume":"29","author":"Mulvihill","year":"2018","journal-title":"Curr Opin Lipidol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-016-0380-y","article-title":"Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study","volume":"15","author":"Leon-Acu\u00f1a","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/01.ATV.0000222015.76038.14","article-title":"Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein b-48\u2013containing lipoproteins in humans","volume":"26","author":"Duez","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1194\/jlr.M040071","article-title":"Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance","volume":"55","author":"Couture","year":"2014","journal-title":"J Lipid Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.2337\/db13-0935","article-title":"Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol","volume":"62","author":"Shojaee-Moradie","year":"2013","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1194\/jlr.M600548-JLR200","article-title":"Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes","volume":"48","author":"Hogue","year":"2007","journal-title":"J Lipid Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1046\/j.1365-2362.2000.00755.x","article-title":"Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study","volume":"30","author":"Duvillard","year":"2000","journal-title":"Eur J Clin Invest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/cob.12118","article-title":"Delayed clearance of triglyceride-rich lipoproteins in young, healthy obese subjects","volume":"5","author":"Larsen","year":"2015","journal-title":"Clin Obes."},{"key":"B28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2337\/db09-1297","article-title":"Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids","volume":"59","author":"Pavlic","year":"2010","journal-title":"Diabetes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2004.02.005","article-title":"Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance","volume":"174","author":"Leung","year":"2004","journal-title":"Atherosclerosis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2337\/db04-1084","article-title":"Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia evidence for activation of protein tyrosine phosphatase-1b, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine","volume":"55","author":"Federico","year":"2006","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"31646","DOI":"10.1074\/jbc.M200544200","article-title":"Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance","volume":"277","author":"Haidari","year":"2002","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"16328","DOI":"10.1074\/jbc.M115.709626","article-title":"Short term palmitate supply impairs intestinal insulin signaling via ceramide production","volume":"291","author":"Tran","year":"2016","journal-title":"J Biol Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.molmet.2014.01.011","article-title":"On ceramides, other sphingolipids and impaired glucose homeostasis","volume":"3","author":"Larsen","year":"2014","journal-title":"Mol Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosissup.2008.05.011","article-title":"Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity","volume":"9","author":"Hsieh","year":"2008","journal-title":"Atheroscler Suppl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.2337\/diabetes.52.10.2539","article-title":"Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes","volume":"52","author":"Zoltowska","year":"2003","journal-title":"Diabetes."},{"key":"B36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1161\/ATVBAHA.113.302993","article-title":"Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects","volume":"34","author":"Veilleux","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2005.08.020","article-title":"Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition","volume":"187","author":"Phillips","year":"2006","journal-title":"Atherosclerosis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1161\/CIRCULATIONAHA.107.739888","article-title":"Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans","volume":"117","author":"Duez","year":"2008","journal-title":"Circulation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides glp-1 and glp-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"Orshov","year":"1986","journal-title":"Endocrinology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.beem.2004.08.001","article-title":"Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2","volume":"18","author":"Baggio","year":"2004","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2337\/db12-0202","article-title":"GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: Evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states","volume":"62","author":"Hein","year":"2013","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2009.05.051","article-title":"Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36","volume":"137","author":"Hsieh","year":"2009","journal-title":"Gastroenterology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1210\/EN.2015-1110","article-title":"Glucagon-like peptide 2 (GLP-2) stimulates postprandial chylomicron production and postabsorptive release of intestinal triglyceride storage pools via induction of nitric oxide signaling in male hamsters and mice","volume":"156","author":"Hsieh","year":"2015","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1053\/j.gastro.2014.08.037","article-title":"Glucagon-like peptide-2 regulates release of chylomicrons from the intestine","volume":"147","author":"Dash","year":"2014","journal-title":"Gastroenterology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1161\/ATVBAHA.119.313011","article-title":"Glucose and GLP-2 (glucagon-like peptide-2) mobilize intestinal triglyceride by distinct mechanisms","volume":"39","author":"Stahel","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2337\/diabetes.52.2.252","article-title":"Role of leptin in the regulation of glucagon-like peptide-1 secretion","volume":"52","author":"Anini","year":"2003","journal-title":"Diabetes."},{"key":"B48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.proghi.2010.06.001","article-title":"Cross-talk between adipose and gastric leptins for the control of food intake and energy metabolism","volume":"45","author":"Cammisotto","year":"2010","journal-title":"Prog Histochem Cytochem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1194\/jlr.M005744","article-title":"An intrinsic gut leptin-melanocortin pathway modulates intestinal microsomal triglyceride transfer protein and lipid absorption","volume":"51","author":"Iqbal","year":"2010","journal-title":"J Lipid Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/ATVBAHA.111.242073","article-title":"Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes","volume":"32","author":"Nogueira","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00125-015-3501-3","article-title":"Obesity-associated intestinal insulin resistance is ameliorated after bariatric surgery","volume":"58","author":"M\u00e4kinen","year":"2015","journal-title":"Diabetologia."},{"key":"B52","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s11695-013-1148-z","article-title":"Early improvement of postprandial lipemia after bariatric surgery in obese type 2 diabetic patients","volume":"24","author":"Griffo","year":"2014","journal-title":"Obes Surg."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1161\/ATVBAHA.114.303849","article-title":"Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans","volume":"34","author":"Padilla","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s001250050700","article-title":"Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM","volume":"40","author":"Malmstr\u00f6m","year":"1997","journal-title":"Diabetologia."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/ATVBAHA.112.300769","article-title":"Novel role of enteral monosaccharides in intestinal lipoprotein production in healthy humans","volume":"33","author":"Xiao","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1161\/ATVBAHA.115.307044","article-title":"Intravenous glucose acutely stimulates intestinal lipoprotein secretion in healthy humans","volume":"36","author":"Xiao","year":"2016","journal-title":"Atheroscler Thromb Vasc Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/15604280214277","article-title":"Defective chylomicron synthesis as a cause of delayed particle clearance in diabetes?","volume":"3","author":"Phillips","year":"2002","journal-title":"Int J Exp Diabetes Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/labinvest.2015.115","article-title":"The expression of genes involved in jejunal lipogenesis and lipoprotein synthesis is altered in morbidly obese subjects with insulin resistance","volume":"95","author":"Gutierrez-Repiso","year":"2015","journal-title":"Lab Invest."},{"key":"B59","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2337\/diacare.17.8.810","article-title":"Apolipoprotein A-IV levels and phenotype distribution in NIDDM","volume":"17","author":"Verges","year":"1994","journal-title":"Diabetes Care."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.jacc.2017.08.053","article-title":"Glycated apolipoprotein A-IV induces atherogenesis in patients with CAD in type 2 diabetes","volume":"70","author":"Dai","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B61","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/S0022-2275(20)37472-1","article-title":"Effects of particle size and number on the plasma clearance of chylomicrons and remnants","volume":"37","author":"Martins","year":"1996","journal-title":"J Lipid Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/014860710302700158","article-title":"Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions","volume":"27","author":"Qi","year":"2003","journal-title":"J Parenter Enter Nutr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/cells8040319","article-title":"Apolipoprotein A-IV: a multifunctional protein involved in protection against atherosclerosis and diabetes","volume":"8","author":"Qu","year":"2019","journal-title":"Cells."},{"key":"B64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyor\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1053\/meta.2000.7744","article-title":"Postprandial apolipoprotein B48\u2013 and B100\u2013containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?","volume":"49","author":"Battula","year":"2000","journal-title":"Metab Clin Exp."},{"key":"B67","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0022-2275(20)30112-7","article-title":"Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test","volume":"43","author":"Chan","year":"2002","journal-title":"J Lipid Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1161\/ATVBAHA.118.310882","article-title":"Comparative effects of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibition and statins on postprandial triglyceride-rich lipoprotein metabolism","volume":"38","author":"Chan","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1194\/jlr.M011080","article-title":"Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men","volume":"52","author":"Tremblay","year":"2011","journal-title":"J Lipid Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2011.03.012","article-title":"Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes","volume":"217","author":"Bozzetto","year":"2011","journal-title":"Atherosclerosis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2337\/dc10-0320","article-title":"Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial","volume":"33","author":"Ruggenenti","year":"2010","journal-title":"Diabetes Care."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3945\/an.113.003798","article-title":"PPAR-\u03b1 as a key nutritional and environmental sensor for metabolic adaptation","volume":"4","author":"Contreras","year":"2013","journal-title":"Adv Nutr."},{"key":"B75","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J Atheroscler Thromb."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0845-x","article-title":"Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis","volume":"18","author":"Ida","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"B78","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice","volume":"133","author":"Takei","year":"2017","journal-title":"J Pharmacol Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein Convertase Subtilisin Kexin Type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"Le May","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein Convertase subtilisin kexin Type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor\u2013dependent and \u2013independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation."},{"key":"B84","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","article-title":"Metformin and the intestine","volume":"51","author":"Bailey","year":"2008","journal-title":"Diabetologia."},{"key":"B86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1185\/03007998409109558","article-title":"Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects","volume":"9","author":"Bonora","year":"1984","journal-title":"Curr Med Res Opin."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2337\/diacare.17.10.1093","article-title":"Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM","volume":"17","author":"Jeppesen","year":"1994","journal-title":"Diabetes Care."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e100778","DOI":"10.1371\/journal.pone.0100778","article-title":"Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus","volume":"9","author":"Napolitano","year":"2014","journal-title":"PLoS ONE."},{"key":"B89","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/dom.12826","article-title":"Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes","volume":"19","author":"Preiss","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jdi.13016","article-title":"Efficacy of metformin on postprandial plasma triglyceride concentration by administration timing in patients with type 2 diabetes mellitus: a randomized cross-over pilot study","volume":"10","author":"Sato","year":"2019","journal-title":"J Diabetes Investig."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"B92","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2337\/dc14-1984","article-title":"Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial","volume":"38","author":"Meier","year":"2015","journal-title":"Diabetes Care."},{"key":"B95","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1210\/jc.2018-01176","article-title":"Lixisenatide reduces chylomicron triacylglycerol by increased clearance","volume":"104","author":"Whyte","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing apoB48 (apolipoprotein B48) catabolism and by reducing apoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"117955141986681","DOI":"10.1177\/1179551419866811","article-title":"Potential impact on lipoprotein subfractions in type 2 diabetes","volume":"12","author":"Kamijo","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"key":"B103","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","article-title":"Interaction of the Sodium\/Glucose Cotransporter. (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2","volume":"358","author":"Ohgaki","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care."},{"key":"B105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1475-2840-12-73","article-title":"Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report","volume":"12","author":"Zheng","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.clinthera.2013.06.011","article-title":"Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.clinthera.2013.01.010","article-title":"Effects of LX4211, a dual SGLT1\/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther."},{"key":"B109","first-page":"817","article-title":"Obesity management: update on orlistat","volume":"3","author":"Drew","year":"2007","journal-title":"Vasc Health Risk Manag."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care."},{"key":"B112","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1152\/ajpendo.90949.2008","article-title":"Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism","volume":"297","author":"Shi","year":"2009","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e0150976","DOI":"10.1371\/journal.pone.0150976","article-title":"Pharmacological inhibition of monoacylglycerol o-acyltransferase 2 improves hyperlipidemia, obesity, and diabetes by change in intestinal fat utilization","volume":"11","author":"Take","year":"2016","journal-title":"PLoS ONE"},{"key":"B114","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1087057116673181","article-title":"Discovery of human intestinal MGAT inhibitors using high-throughput mass spectrometry","volume":"22","author":"Adachi","year":"2017","journal-title":"SLAS Discov Adv Life Sci RD."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1194\/jlr.M029041","article-title":"Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying","volume":"53","author":"Ables","year":"2012","journal-title":"J Lipid Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e00193","DOI":"10.1002\/prp2.193","article-title":"Potential mechanism of enhanced postprandial glucagon-like peptide-1 release following treatment with a diacylglycerol acyltransferase 1 inhibitor","volume":"3","author":"Liu","year":"2015","journal-title":"Pharmacol Res Perspect."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/oby.20193","article-title":"Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight and modulates gut peptide release\u2013potential insight into mechanism of action","volume":"21","author":"Liu","year":"2013","journal-title":"Obes Silver Spring Md."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis."},{"key":"B119","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/dom.12221","article-title":"Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial","volume":"16","author":"Denison","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"B120","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1172\/JCI64873","article-title":"DGAT1 mutation is linked to a congenital diarrheal disorder","volume":"122","author":"Haas","year":"2012","journal-title":"J Clin Invest."},{"key":"B121","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jacl.2014.02.021","article-title":"Diacylglycerol acyltransferase 1 (DGAT1) inhibition as a metabolic regulator: clinical benefits of pradigastat in obese patients with type 2 diabetes","volume":"8","author":"Kjems","year":"2014","journal-title":"J Clin Lipidol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4291\/wjgp.v8.i4.161","article-title":"Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion","volume":"8","author":"Maciejewski","year":"2017","journal-title":"World J Gastrointest Pathophysiol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12986-015-0025-2","article-title":"Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial","volume":"12","author":"Velliquette","year":"2015","journal-title":"Nutr Metab."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JPRI\/2017\/36835","article-title":"A novel acyl-CoA: diacylglycerol acyltransferase 1. (DGAT1) inhibitor, GSK2973980A, inhibits postprandial triglycerides and reduces body weight in a rodent diet-induced obesity model","volume":"18","author":"Kumar","year":"2017","journal-title":"J Pharm Res Int"},{"key":"B125","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.22980","article-title":"Specific role for acyl CoA: diacylglycerol acyltransferase 1. (Dgat1) in hepatic steatosis due to exogenous fatty acids","volume":"50","author":"Villanueva","year":"2009","journal-title":"Hepatology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J Biol Chem"},{"key":"B127","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: Thirteen years' treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/clp.13.74","article-title":"Lomitapide: a novel drug for homozygous familial hypercholesterolemia","volume":"9","author":"Panno","year":"2014","journal-title":"Clin Lipidol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40264-014-0147-x","article-title":"Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition","volume":"37","author":"Lin","year":"2014","journal-title":"Drug Saf."},{"key":"B130","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1124\/jpet.110.173807","article-title":"Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4\u2032-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate. (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein","volume":"336","author":"Mera","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"B131","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jphs.2015.10.004","article-title":"JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates lipid metabolism and attenuates atherosclerosis in hyperlipidemic animal models","volume":"129","author":"Mera","year":"2015","journal-title":"J Pharmacol Sci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1124\/jpet.110.177527","article-title":"A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090, biochemical, pharmacodynamic, pharmacokinetic and safety profile","volume":"337","author":"Kim","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.14309\/00000434-200509001-00238","article-title":"SLx-4090: A novel, intestinal-specific mtp inhibitor for lowering plasma triglyceride and cholesterol levels in dyslipidemia","volume":"100","author":"Sweetnam","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"B134","article-title":"Clinical investigations of SLx-4090 in combination with metformin in type 2 diabetics","author":"Tong","year":"2010","journal-title":"70th Scientific Sessions"},{"key":"B135","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver","volume":"26","author":"Windler","year":"1985","journal-title":"J Lipid Res."},{"key":"B136","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J Lipid Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2004.06.011","article-title":"Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia","volume":"177","author":"Cohn","year":"2004","journal-title":"Atherosclerosis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s001250051537","article-title":"Severe hypertriglyceridaemia in type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 deficiency","volume":"43","author":"Mar\u00e7ais","year":"2000","journal-title":"Diabetologia."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"Cohn","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B141","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1194\/jlr.M900346-JLR200","article-title":"Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions","volume":"51","author":"Sundaram","year":"2010","journal-title":"J Lipid Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e00247","DOI":"10.1002\/phy2.247","article-title":"Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph","volume":"2","author":"Wang","year":"2014","journal-title":"Physiol Rep."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1194\/jlr.M093740","article-title":"ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance","volume":"60","author":"Ramms","year":"2019","journal-title":"J Lipid Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.4390","article-title":"A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels","volume":"23","author":"Khetarpal","year":"2017","journal-title":"Nat Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00125-018-4604-4","article-title":"Can targeting ANGPTL proteins improve glucose tolerance?","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia."},{"key":"B146","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.molmet.2017.06.007","article-title":"Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting","volume":"6","author":"Cushing","year":"2017","journal-title":"Mol Metab."},{"key":"B148","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molmet.2013.11.004","article-title":"Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion","volume":"3","author":"Mattijssen","year":"2014","journal-title":"Mol Metab."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.bbrc.2012.07.038","article-title":"Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels","volume":"424","author":"Zhang","year":"2012","journal-title":"Biochem Biophys Res Commun."},{"key":"B152","doi-asserted-by":"publisher","first-page":"36926","DOI":"10.1038\/srep36926","article-title":"Fasting and feeding signals control the oscillatory expression of ANGPTL8 to modulate lipid metabolism","volume":"6","author":"Dang","year":"2016","journal-title":"Sci Rep."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T22:17:36Z","timestamp":1614809856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":152,"alternative-id":["10.3389\/fendo.2020.00116"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00116","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"article-number":"116"}}